Comparison of cytology and nuclear matrix protein 22 for the detection and follow-up of bladder cancer

Urologia Internationalis

Volumn 66, Issue 2, 2001, Pages 72-77

  Lahme, Sven ^a   Bichler, Karl Horst ^a   Feil, Gerhard ^a   Krause, Steffen ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder; Carcinoma; Cytology; Nuclear matrix proteins; Transitional cell

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RELIABILITY; URINE CYTOLOGY;

CARCINOMA, TRANSITIONAL CELL; FOLLOW-UP STUDIES; HUMANS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0035104989     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056574     Document Type: Article

References (14)

1. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: Comparison with urinary cytology and BTA test
2. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer
3. Sensitivity and specificity of NMP-22, telomerase and BTA in the detection of human bladder cancer
4. Nuclear matrix protein (NMP-22) - A powerful urine marker in tumor screening and follow-up in bladder cancer
5. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat
6. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder
7. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract
8. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria
9. Use of a new tumor marker, urinary NMP22 in the detection of occult or rapidly recuring transitional cell carcinoma of the urinary tract following surgical treatment
10. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer
11. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder
12. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker
13. Comparison of screening methods in the detection of bladder cancer
14. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: Experience on 137 patients